

1614

ATTORNEY DOCKET NO. 21101.0026U2
PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

| | | |
|---|---|-------------------------------|
| In re Application of |) | |
| |) | |
| Kuwada |) | Group Art No.: 1614 |
| |) | |
| Application No. 10/505,244 |) | Examiner: Paulette R. Kidwell |
| |) | |
| International Filing Date: 21 February 2003 |) | Confirmation No.: 7587 |
| |) | |
| For: |) | |

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

Mail Stop Amendment
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

NEEDLE & ROSENBERG, P.C.
Customer No. 23859

Sir:

Pursuant to the requirements of 37 C.F.R. § 1.56, submitted herewith on the accompanying Information Disclosure Statement List is a listing of documents known to Applicants and/or their attorneys. In accordance with 37 C.F.R. § 1.98(a)(2), copies of any cited U.S. patent or U.S. patent application publication documents are not enclosed. Copies of any cited foreign patent document and/or any non-patent publication are enclosed.


This Information Disclosure Statement is believed to be filed in a timely manner pursuant to 37 C.F.R. § 1.97(b)(3), in that a first Office Action on the merits of the present patent application has not yet been mailed to Applicants.

Consideration of the cited documents and making the same of record in the prosecution of the above-referenced application are respectfully requested.

No fee is believed due; however, the Commissioner is hereby authorized to charge any additional fees which may be required, or credit any overpayment to Deposit Account No. 14-0629.

Respectfully submitted,


NEEDLE & ROSENBERG, P.C.


Janell T. Cleveland
Patent Agent
Registration No. 53,848


NEEDLE & ROSENBERG, P.C.
Customer Number 23859
(678) 420-9300
(678) 420-9301 (fax)

CERTIFICATE OF MAILING UNDER 37 C.F.R. § 1.8

I hereby certify that this correspondence, including any items indicated as attached or included, is being deposited with the United States Postal Service as first class mail in an envelope addressed to: Mail Stop Amendment, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450, on the date indicated below.


Janell T. Cleveland

May 12, 2005
Date



Information Disclosure Statement List

(Use as many sheets as necessary)

Complete if Known

| | |
|----------------------|-------------------|
| Application Number | 10/505,244 |
| Intl. Filing Date | February 21, 2003 |
| First Named Inventor | Kuwada |
| Group Art Unit | Unassigned |
| Examiner Name | Unassigned |

U.S. PATENT DOCUMENTS

| Examiner's Initials | Cite No. | Document No. | Date | Name | Class | Subclass | Filing Date (if appropriate) |
|---------------------|----------|--------------|------|------|-------|----------|------------------------------|
| | | | | | | | |

FOREIGN PATENT DOCUMENTS

| Examiner's Initials | Cite No. | Foreign Patent Document Country Code-Number-Kind Code | Date | Name | Translation Yes/No |
|---------------------|----------|--|------|------|-----------------------|
| | | | | | |

NON-PATENT DOCUMENTS

| Examiner's Initials | Cite No. | Non-Patent Citations (include Author, Title, Publisher, Relevant Pages, Date and Place of Publication) |
|---------------------|----------|---|
| /A.P./ | B1 | Alkalay et al. (1995). Stimulation-dependent I kappa B alpha phosphorylation marks the NF-B inhibitor for degradation via the ubiquitin-proteasome pathway, Proc Natl Acad Sci U S A 92, 10599-10603 |
| /A.P./ | B2 | Aoudjit and Vuori, (2001). Matrix attachment regulates Fas-induced apoptosis in endothelial cells: a role for c-flip and implications for anoikis, J Cell Biol 152, 633-643 |
| /A.P./ | B3 | Battu et al. (1998). Cyclooxygenase-2 expression in human adenocarcinoma cell line HT29 cl.19A, Anticancer Res 18, 2397-2403 |
| /A.P./ | B4 | Beg et al. (1992). I kappa B interacts with the nuclear localization sequences of the subunits of NF-kB: a mechanism for cytoplasmic retention, Genes Dev 6, 1899-1913 |
| /A.P./ | B5 | Boland, (1999). Malignant Tumors of the Colon. In Textbook of Gastroenterology, T. Yamada, D. H. Alpers, L. Laine, C. Owyang, and D. W. Powell, eds. (Philadelphia, Lippincott Williams and Wilkins), pp. 2023-2082 |
| /A.P./ | B6 | Cao et al. (1998). Interleukin 15 protects against toxicity and potentiates antitumor activity of 5-fluorouracil alone and in combination with leucovorin in rats bearing colorectal cancer, Cancer Res 58, 1695-1699 |
| /A.P./ | B7 | Chambers et al. (1995). Steps in tumor metastasis: new concepts from intravital videomicroscopy, Cancer Metastasis Rev 14, 279-301 |
| /A.P./ | B8 | Chen et al. (1995). Signal-induced site-specific phosphorylation targets I kappa B alpha to the ubiquitin-proteasome pathway, Genes Dev 9, 1586-1597 |
| /A.P./ | B9 | Crofford et al. (1997). Involvement of nuclear factor kappa B in the regulation of cyclooxygenase-2 expression by interleukin-1 in rheumatoid synoviocytes, Arthritis Rheum 40, 226-236 |
| /A.P./ | B10 | Darmoul et al. (2001). Initiation of human colon cancer cell proliferation by trypsin acting at protease-activated receptor-2, Br J Cancer 85, 772-779 |
| /A.P./ | B11 | D'Haens et al. (1999). Endoscopic and histological healing with infliximab anti-tumor necrosis factor antibodies in Crohn's disease: A European multicenter trial, Gastroenterology 116, 1029-1034 |
| /A.P./ | B12 | DiDonato et al. 1996). Mapping of the inducible IkappaB phosphorylation sites that signal its ubiquitination and degradation, Mol Cell Biol 16, 1295-1304 |
| /A.P./ | B13 | DuBois et al. (1996). Nonsteroidal anti-inflammatory drugs, eicosanoids, and colorectal cancer prevention, Gastroenterol Clin North Am 25, 773-791 |
| /A.P./ | B14 | Eberhart et al. (1994). Up-regulation of cyclooxygenase 2 gene expression in human colorectal adenomas and adenocarcinomas, Gastroenterology 107, 1183-1188 |


Examiner Signature:

/Anna Pagonakis/

Date Considered:

05/16/2008

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.



Information Disclosure Statement List

(Use as many sheets as necessary)

Complete if Known

| | |
|----------------------|-------------------|
| Application Number | 10/505,244 |
| Intl. Filing Date | February 21, 2003 |
| First Named Inventor | Kuwada |
| Group Art Unit | Unassigned |
| Examiner Name | Unassigned |

| | | |
|--------|-----|--|
| /A.P./ | B15 | Elder et al. (1997). Induction of apoptotic cell death in human colorectal carcinoma cell lines by a cyclooxygenase-2 (COX-2)-selective nonsteroidal anti-inflammatory drug: independence from COX-2 protein expression, Clin Cancer Res 3, 1679-1683 |
| /A.P./ | B16 | Elnemr et al. (2001). Human pancreatic cancer cells disable function of Fas receptors at several levels in Fas signal transduction pathway, Int J Oncol 18, 311-316 |
| /A.P./ | B17 | Engers and Gabbert, (2000). Mechanisms of tumor metastasis: cell biological aspects and clinical implications, J Cancer Res Clin Oncol 126, 682-692 |
| /A.P./ | B18 | Frisch and Francis, (1994). Disruption of epithelial cell-matrix interactions induces apoptosis, J Cell Biol 124, 619-626 |
| /A.P./ | B19 | Giri and Aggarwal, (1998). Constitutive activation of NF- κ B causes resistance to apoptosis in human cutaneous T cell lymphoma HuT-78 cells. Autocrine role of tumor necrosis factor and reactive oxygen intermediates, J Biol Chem 273, 14008-14014 |
| /A.P./ | B20 | Golab et al. (2000). Interleukin 12 and indomethacin exert a synergistic, angiogenesis-dependent antitumor activity in mice, Life Sci 66, 1223-1230 |
| /A.P./ | B21 | Groden et al. (1995). Response of colon cancer cell lines to the introduction of APC, a colon-specific tumor suppressor gene, Cancer Res 55, 1531-1539 |
| /A.P./ | B22 | Han et al. (2000). Activation of NF- κ B determines the sensitivity of human colon cancer cells to TNF α -induced apoptosis, Biol Pharm Bull 23, 420-426 |
| /A.P./ | B23 | Hansen et al. (1995). Tumor cells in blood shed from the surgical field, Arch Surg 130, 387-393 |
| /A.P./ | B24 | Hansen et al. (1999). Blood irradiation for intraoperative autotransfusion in cancer surgery: demonstration of efficient elimination of contaminating tumor cells, Transfusion 39, 608-615 |
| /A.P./ | B25 | He et al. (1999). PPAR δ is an APC-regulated target of nonsteroidal anti-inflammatory drugs, Cell 99, 335-345 |
| /A.P./ | B26 | Henkel et al. (1993). Rapid proteolysis of I kappa B-alpha is necessary for activation of transcription factor NF- κ B, Nature 365, 182-185 |
| /A.P./ | B27 | Higgins et al. (1993). Antisense inhibition of the p65 subunit of NF- κ B blocks tumorigenicity and causes tumor regression, Proc Natl Acad Sci U S A 90, 9901-9905 |
| /A.P./ | B28 | Hsi et al. 2000). Lack of cyclooxygenase-2 activity in HT-29 human colorectal carcinoma cells, Exp Cell Res 256, 563-570 |
| /A.P./ | B29 | Huang et al. (2001). Blockade of NF- κ B activity in human prostate cancer cells is associated with suppression of angiogenesis, invasion, and metastasis, Oncogene 20, 4188-4197 |
| /A.P./ | B30 | Ichijo et al.. (1997). Induction of apoptosis by ASK1, a mammalian MAPKKK that activates SAPK/JNK and p38 signaling pathways, Science 275, 90-94 |
| /A.P./ | B31 | Ilyas et al.. (1997). Beta-catenin mutations in cell lines established from human colorectal cancers, Proc Natl Acad Sci U S A 94, 10330-10334 |
| /A.P./ | B32 | Irmeler et al. (1997). Inhibition of death receptor signals by cellular FLIP, Nature 388, 190-195 |
| | B33 | Jung et al. (1995). A distinct array of proinflammatory cytokines is expressed in human colon epithelial cells in response to bacterial invasion, J Clin Invest 95, 55-65 |
| /A.P./ | B34 | Kreuz et al. (2001). NF- κ B inducers upregulate cFLIP, a cycloheximide-sensitive inhibitor of death receptor signaling, Mol Cell Biol 21, 3964-3973 |
| /A.P./ | B35 | Kutchera et al. (1996). Prostaglandin H synthase 2 is expressed abnormally in human colon cancer: evidence for a transcriptional effect, Proc Natl Acad Sci U S A 93, 4816-4820 |


Examiner Signature:

/Anna Pagonakis/

Date Considered:

05/16/2008

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.



Information Disclosure Statement List

(Use as many sheets as necessary)

Complete if Known

| | |
|----------------------|-------------------|
| Application Number | 10/505,244 |
| Intl. Filing Date | February 21, 2003 |
| First Named Inventor | Kuwada |
| Group Art Unit | Unassigned |
| Examiner Name | Unassigned |

| | | |
|--------|-----|---|
| /A.P./ | B36 | Lee and Juliano, (2000). alpha5beta1 integrin protects intestinal epithelial cells from apoptosis through a phosphatidylinositol 3-kinase and protein kinase B- dependent pathway, Mol Biol Cell 11, 1973-1987 |
| /A.P./ | B37 | Liefers et al. (1998). Micrometastases and survival in stage II colorectal cancer, N Engl J Med 339, 223-228 |
| /A.P./ | B38 | Liotta et al. (1974). Quantitative relationships of intravascular tumor cells, tumor vessels, and pulmonary metastases following tumor implantation, Cancer Res 34, 997-1004 |
| /A.P./ | B39 | Martin, (1996). Normal Cells and Cancer Cells. In Molecular Oncology, J. M. Bishop, and R. A. Weinberg, eds. (New York, Scientific American), pp. 13-40 |
| /A.P./ | B40 | Mehes et al. (2001). Circulating breast cancer cells are frequently apoptotic, Am J Pathol 159, 17-20. |
| /A.P./ | B41 | Meredith et al. (1993). The extracellular matrix as a cell survival factor, Mol Biol Cell 4, 953-961 |
| /A.P./ | B42 | Munemitsu et al. (1995). Regulation of intracellular beta-catenin levels by the adenomatous polyposis coli (APC) tumor-suppressor protein, Proc Natl Acad Sci U S A 92, 3046-3050 |
| /A.P./ | B43 | Newton et al. (1997). Evidence for involvement of NF- κ B in the transcriptional control of COX-2 gene expression by IL-1beta, Biochem Biophys Res Commun 237, 28-32 |
| /A.P./ | B44 | Newton et al. (1997). Superinduction of COX-2 mRNA by cycloheximide and interleukin-1beta involves increased transcription and correlates with increased NF- κ B and JNK activation, FEBS Lett 418, 135-138 |
| /A.P./ | B45 | Nicolson, (1991). Gene expression, cellular diversification and tumor progression to the metastatic phenotype, Bioessays 13, 337-342 |
| /A.P./ | B46 | Palombella et al. (1994). The ubiquitin-proteasome pathway is required for processing the NF- κ B 1 precursor protein and the activation of NF- κ B, Cell 78, 773-785 |
| /A.P./ | B47 | Peleg et al. (1996). Long-term use of nonsteroidal antiinflammatory drugs and other chemopreventors and risk of subsequent colorectal neoplasia, Dig Dis Sci 41, 1319-1326 |
| /A.P./ | B48 | Pierce et al. (1997). Novel inhibitors of cytokine-induced IkappaBalpha phosphorylation and endothelial cell adhesion molecule expression show anti-inflammatory effects in vivo, J Biol Chem 272, 21096-21103 |
| /A.P./ | B49 | Remacle-Bonnet et al. (2000). Insulin-like growth factor-I protects colon cancer cells from death factor-induced apoptosis by potentiating tumor necrosis factor alpha- induced mitogen-activated protein kinase and nuclear factor kappaB signaling pathways, Cancer Res 60, 2007-2017 |
| /A.P./ | B50 | Renard et al. (2001). Development of a sensitive multi-well colorimetric assay for active NF- κ B, Nucleic Acids Res 29, No.4e21 |
| /A.P./ | B51 | Rosette and Karin, (1996). Ultraviolet light and osmotic stress: activation of the JNK cascade through multiple growth factor and cytokine receptors, Science 274, 1194-1197. |
| /A.P./ | B52 | Rubinfeld et al. (1995). The APC protein and E-cadherin form similar but independent complexes with alpha-catenin, beta-catenin, and plakoglobin, J Biol Chem 270, 5549-5555 |
| /A.P./ | B53 | Ryu et al. (2001). Increased expression of cFLIP(L) in colonic adenocarcinoma, J Pathol 194, 15-19 |
| /A.P./ | B54 | Schmedtje et al. (1997). Hypoxia induces cyclooxygenase-2 via the NF- κ B p65 transcription factor in human vascular endothelial cells, J Biol Chem 272, 601-608 |

Examiner Signature:

/Anna Pagonakis/


Date Considered:

05/16/2008

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.



| Information Disclosure Statement List (Use as many sheets as necessary) | | | Complete if Known | |
|---|-----|--|--------------------------------|-------------------|
| | | | Application Number | 10/505,244 |
| | | | Intl. Filing Date | February 21, 2003 |
| | | | First Named Inventor | Kuwada |
| | | | Group Art Unit | Unassigned |
| | | | Examiner Name | Unassigned |
| /A.P./ | B55 | Schwartz et al. (1999). The role of NF- κ B / I κ B proteins in cancer: implications for novel treatment strategies., Surgical Oncology 8, 143-153 | | |
| /A.P./ | B56 | Shanmugathan and Jothy, (2000). Apoptosis, anoikis and their relevance to the pathobiology of colon cancer, Pathol Int 50, 273-279 | | |
| /A.P./ | B57 | Shao et al. (2000). Regulation of constitutive cyclooxygenase-2 expression in colon carcinoma cells, J Biol Chem 275, 33951-33956 | | |
| /A.P./ | B58 | Sheng et al. (1997). Inhibition of human colon cancer cell growth by selective inhibition of cyclooxygenase-2, J Clin Invest 99, 2254-2259 | | |
| /A.P./ | B59 | Shiff et al. (1995). Sulindac sulfide, an aspirin-like compound, inhibits proliferation, causes cell cycle quiescence, and induces apoptosis in HT-29 colon adenocarcinoma cells, J Clin Invest 96, 491-503 | | |
| /A.P./ | B60 | Shinohara et al. (1998). Prevention of intestinal toxic effects and intensification of irinotecan's therapeutic efficacy against murine colon cancer liver metastases by oral administration of the lipopeptide JBT 3002, Clin Cancer Res 4, 2053-2063 | | |
| /A.P./ | B61 | Shureiqi et al. (1999). Decreased 13-S-hydroxyoctadecadienoic acid levels and 15-lipoxygenase-1 expression in human colon cancers, Carcinogenesis 20, 1985-1995 | | |
| /A.P./ | B62 | Shureiqi et al. (2000). 15-LOX-1: a novel molecular target of nonsteroidal anti-inflammatory drug-induced apoptosis in colorectal cancer cells, J Natl Cancer Inst 92, 1136-1142 | | |
| /A.P./ | B63 | Singh and Trotman, (1998). Use and safety of aspirin in the chemoprevention of colorectal cancer, J Assoc Acad Minor Phys 9, 40-44 | | |
| /A.P./ | B64 | Sinicropo et al. (1996). Phase I trial of sulindac plus 5-fluorouracil and levamisole: potential adjuvant therapy for colon carcinoma, Clin Cancer Res 2, 37-41. | | |
| /A.P./ | B65 | Smalley and DuBois, (1997). Colorectal cancer and nonsteroidal anti-inflammatory drugs, Adv Pharmacol 39, 1-20 | | |
| /A.P./ | B66 | Sokoloski et al. (1993). Antisense oligonucleotides to the p65 subunit of NF- κ B block CD11b expression and alter adhesion properties of differentiated HL-60 granulocytes, Blood 82, 625-632 | | |
| /A.P./ | B67 | Stehlik et al. (1998). Nuclear factor (NF)- κ B-regulated X-chromosome-linked iap gene expression protects endothelial cells from tumor necrosis factor alpha- induced apoptosis, J Exp Med 188, 211-216 | | |
| /A.P./ | B68 | Strater et al. (1996). Rapid onset of apoptosis in vitro follows disruption of beta 1-integrin/matrix interactions in human colonic crypt cells, Gastroenterology 110, 1776-1784 | | |
| /A.P./ | B69 | Tepper and Seldin, (1999). Modulation of caspase-8 and FLICE-inhibitory protein expression as a potential mechanism of Epstein-Barr virus tumorigenesis in Burkitt's lymphoma, Blood 94, 1727-1737 | | |
| /A.P./ | B70 | Traenckner et al. 1995). Phosphorylation of human I κ B-alpha on serines 32 and 36 controls I kappa B-alpha proteolysis and NF- κ B activation in response to diverse stimuli, Embo J 14, 2876-2883 | | |
| /A.P./ | B71 | Tsuji et al. (1996). Evidences for involvement of cyclooxygenase-2 in proliferation of two gastrointestinal cancer cell lines, Prostaglandins Leukot Essent Fatty Acids 55, 179-183 | | |
| /A.P./ | B72 | Tsuji and DuBois, (1995). Alterations in cellular adhesion and apoptosis in epithelial cells overexpressing prostaglandin endoperoxide synthase 2, Cell 83, 493-501 | | |
| /A.P./ | B73 | Wang et al. (1999). Control of inducible chemoresistance: enhanced anti-tumor therapy through increased apoptosis by inhibition of NF- κ B, Nat Med 5, 412-417 | | |
| Examiner Signature: /Anna Pagonakis/ | | | Date Considered: 05/16/2008 | |
| EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. | | | | |



Information Disclosure Statement List

(Use as many sheets as necessary)

Complete if Known

| | |
|----------------------|-------------------|
| Application Number | 10/505,244 |
| Intl. Filing Date | February 21, 2003 |
| First Named Inventor | Kuwada |
| Group Art Unit | Unassigned |
| Examiner Name | Unassigned |

| | | |
|--------|-----|---|
| /A.P./ | B74 | Wang, et al. (1998). NF- κ B antiapoptosis: induction of TRAF1 and TRAF2 and c-IAP1 and c-IAP2 to suppress caspase-8 activation, <i>Science</i> 281, 1680-1683 |
| /A.P./ | B75 | Weiss, (1985). Metastatic inefficiency. In <i>Liver Metastasis</i> , L. Weiss, and H. Gilbert, eds. (Boston, Hall), pp. 126-157 |
| /A.P./ | B76 | Wu et al. (1998). IEX-1L, an apoptosis inhibitor involved in NF- κ B -mediated cell survival, <i>Science</i> 281, 998-1001 |
| /A.P./ | B77 | Yamamoto et al. (1999). Sulindac inhibits activation of the NF- κ B pathway, <i>J Biol Chem</i> 274, 27307-27314 |
| /A.P./ | B78 | Yin et al. (1998). The anti-inflammatory agents aspirin and salicylate inhibit the activity of I κ B kinase-beta, <i>Nature</i> 396, 77-80 |

Examiner Signature:

/Anna Pagonakis/

Date Considered:

05/16/2008

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.